Key facts
- Notable investors include Plug and Play Tech Center, Spacecadet Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Omos Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Omos Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Omos Biosciences
Operator of a biotechnology platform focused on transforming cancer prevention designed to make pre-cancerous conditions treatable before they become malignant. The company offers a strategy that leverages deep phenotyping of clinical samples to build models that unravel the biological changes driving pre-cancerous conditions toward malignancy, enabling customers to stratify the risk of malignancy in patients and develop therapeutic assets for pre-cancer conditions where surgery is risky or has a low chance of success.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2025
- Employees
- 2
- Website
- omos.bio/
- Ownership
- Privately Held (backing)
Omos Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Omos Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Omos Biosciences in its N-PORT filings yet. We sweep new filings monthly.